$4.0471
-0.0429[-1.05%]
At close: May 17
$4.0471
0[0.00%]
After Hours: 9:21AM EDT
ADC Therapeutics
(NYSE:ADCT)Latest News for ADC Therapeutics Stock (NYSE:ADCT)
ADC Therapeutics Stock (NYSE: ADCT)
Categories: All
Tuesday, May 07, 2024
Monday, May 06, 2024
- BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market SessionAvi Kapoor - May 6, 2024, 7:32AM
- ADC Therapeutics Currently Expects Its Cash Runway To Extend Into Q4 Of 2025Benzinga Newsdesk - May 6, 2024, 6:14AM
- ADC Therapeutics Q1 2024 Adj EPS $(0.38) Beats $(0.56) Estimate, Sales $18.053M Miss $18.102M EstimateBenzinga Newsdesk - May 6, 2024, 6:12AM
- ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA in Patients with Relapsed/Refractory Marginal Zone LymphomaBenzinga Newsdesk - May 6, 2024, 6:04AM
Tuesday, April 30, 2024
Monday, April 15, 2024
Friday, April 05, 2024
Thursday, April 04, 2024
- ADC Therapeutics shares are trading higher. The company announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA in combination with glofitamab or mosunetuzumab in heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.Benzinga Newsdesk - Apr 4, 2024, 10:50AM
- ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin LymphomaBenzinga Newsdesk - Apr 4, 2024, 7:05AM
Thursday, March 28, 2024
- ADC Therapeutics shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a price target of $11.Benzinga Newsdesk - Mar 28, 2024, 11:32AM
- Guggenheim Initiates Coverage On ADC Therapeutics with Buy Rating, Announces Price Target of $11Benzinga Newsdesk - Mar 28, 2024, 6:45AM
Thursday, March 14, 2024
Wednesday, March 13, 2024
- Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On WednesdayAvi Kapoor - Mar 13, 2024, 10:22AM
- ADC Therapeutics' 2023 Cash And Cash Equivalents Of $278.6M Is Expected To Provide Cash Runway Into Fourth Quarter Of 2025Benzinga Newsdesk - Mar 13, 2024, 7:04AM
- ADC Therapeutics Q4 Adjusted EPS $(0.97) May Not Be Comparable To $(0.50) Estimate, Sales $16.79M Beat $15.33M EstimateBenzinga Newsdesk - Mar 13, 2024, 7:02AM
- Earnings Scheduled For March 13, 2024Benzinga Insights - Mar 13, 2024, 6:15AM
Tuesday, March 12, 2024
Wednesday, March 06, 2024
Tuesday, March 05, 2024
Monday, February 26, 2024
- ADC Therapeutics shares are trading higher after RBC Capital maintained an Outperform rating on the stock and raised its price target from $6 to $8Benzinga Newsdesk - Feb 26, 2024, 11:47AM
- RBC Capital Maintains Outperform on ADC Therapeutics, Raises Price Target to $8Benzinga Newsdesk - Feb 26, 2024, 10:21AM
Tuesday, February 20, 2024
Thursday, January 04, 2024
Monday, November 20, 2023
Thursday, November 09, 2023
Wednesday, November 08, 2023
Tuesday, November 07, 2023
- ADC Therapeutics Sees Continued Decrease In Total Operating Expenses In FY23 And FY24 As Compared to FY22; Expected Cash Runway Into Middle of 2025Benzinga Newsdesk - Nov 7, 2023, 7:17AM
- ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing StandardsBenzinga Newsdesk - Nov 7, 2023, 7:16AM
- ADC Therapeutics Q3 Adj. EPS $(0.41) Beats $(0.63) Estimate, Sales $14.49M Miss $15.99M EstimateBenzinga Newsdesk - Nov 7, 2023, 7:13AM
- Earnings Scheduled For November 7, 2023Benzinga Insights - Nov 7, 2023, 6:34AM